Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review. (2nd January 2021)

• Record Type: Journal Article
• Authors: Khadka, Sitaram; Nisar, Shameem; Syed, Nawazish-i-Husain; Shrestha, Dhan Bahadur; Budhathoki, Pravash
• Is Part Of: Immunopharmacology and immunotoxicology. Volume 43:Number 1(2021)
• Page Start: 30
• Page End: 36
• Publication Date: 2021-01-02
• Subjects: Convalescent plasma therapy -- coronavirus -- COVID-19 -- pandemic -- rational practice; Immunopharmacology -- Periodicals; Immunotoxicology -- Periodicals; Antibody-toxin conjugates -- Periodicals; Immunology -- Periodicals; 615.37
• DOI: 10.1080/08923973.2020.1863983
• Languages: English
• ISSNs: 0892-3973

Abstract

Abstract: The novel coronavirus disease (COVID-19) has been declared a pandemic by the World Health Organization (WHO) and is ominously threatening the survival of humankind on the whole planet. With a quick spread of the outbreak from its origin, Wuhan, China, to almost all over the world, it has affected more than seven million people to date, hence it has devastated every part of the infrastructural skeleton of governance. Continuously escalating disease burden and lack of proven therapeutic approaches are mounting challenges to health scientists and ultimately to healthcare providers. Although recent studies have shown benefits in decreasing the severity and duration of the illness and there are more benefits compared to risks, plasma therapy cannot be considered as a standard of care until the ongoing trials are completed and they establish definite evidence on its therapeutic efficacy and safety. Though a beneficial aspect may be there, acquiring donors and adequate availability of plasma is equally challenging, and its associated untoward effects related to biological therapeutic agents. The rational practice of CP therapy guided by risk-benefit judgment from aspects of donor and recipient can be a therapeutic option in such a global health crisis.